All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Efficacy of Budesonide and Formoterol Inhalation Aerosol in Conjunction with Doxofylline in Chronic Obstructive Pulmonary Disease

Author(s): Yanling Jiang*, Qingming Meng, Junjie Chen and Shuo Chen
Department of Respiratory and Critical Care Medicine, 1Department of Medicine, The First Hospital of Zhangjiakou, Hebei Province, 075400, 2Department of Respiratory Medicine, 81st Group Military Hospital, People’s Liberation Army, Zhangjiakou, Hebei Province 427000, China

Correspondence Address:
Yanling Jiang, Department of Respiratory and Critical Care Medicine, The First Hospital of Zhangjiakou, Hebei Province, 075400, China, E-mail: mqm133551@163.com


To observe the clinical efficacy of budesonide/formoterol inhalation aerosol in conjunction with doxofylline in treating individuals with stable chronic obstructive pulmonary disease. Our study enrolled a total of 90 patients with stable chronic obstructive pulmonary disease, who were admitted to our hospital from September 2019 to June 2021. These participants were allocated randomly into two groups; the control group and the observation group, comprising 45 patients in each group. Doxofylline was administered to the control group, while the observation group received additional treatment of budesonide/formoterol inhalation aerosol alongside doxofylline. The duration of treatment for both groups was set at 6 mo. The clinical efficacy was determined by evaluating the improvement of clinical symptoms, along with the assessment of pulmonary function, and the measurement of serum levels of interleukin-8, transforming growth factor-beta 1, and tumor necrosis factor-alpha. With a total effective rate of 99.33 %, the observation group outperformed the control group, which achieved a rate of 73.33 %. The baseline measurements of pulmonary function indicators, as well as interleukin-8, transforming growth factor-beta 1, and tumor necrosis factor-alpha levels, showed no remarkable distinctions between the two groups. However, post-treatment evaluations revealed noteworthy improvements in the observation group's forced expiratory volume in the first second/forced vital capacity values compared to their respective pre-treatment levels. These improvements were notably higher than those observed in the control group (p<0.05). Additionally, the observation group exhibited a more substantial decrease in interleukin-8, tumor necrosis factor-alpha, and transforming growth factor-beta 1 levels compared to the control group. Furthermore, no significant difference was observed in the incidence of adverse reactions between the two groups (p>0.05). Budesonide/formoterol inhalation aerosol in conjunction with doxofylline in treating individuals with stable chronic obstructive pulmonary disease significantly improves clinical symptoms, enhances pulmonary function, exhibits good anti-inflammatory effects, and has a good safety profile.

Full-Text | PDF

 
 
Google scholar citation report
Citations : 69022

Indian Journal of Pharmaceutical Sciences received 69022 citations as per google scholar report